These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

162 related articles for article (PubMed ID: 23888956)

  • 1. Epigenetic modification restores functional PR expression in endometrial cancer cells.
    Yang S; Xiao X; Jia Y; Liu X; Zhang Y; Wang X; Winters CJ; Devor EJ; Meng X; Thiel KW; Leslie KK
    Curr Pharm Des; 2014; 20(11):1874-80. PubMed ID: 23888956
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Inverse Relationship between Progesterone Receptor and Myc in Endometrial Cancer.
    Kavlashvili T; Jia Y; Dai D; Meng X; Thiel KW; Leslie KK; Yang S
    PLoS One; 2016; 11(2):e0148912. PubMed ID: 26859414
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Panobinostat Enhances Growth Suppressive Effects of Progestin on Endometrial Carcinoma by Increasing Progesterone Receptor and Mitogen-Inducible Gene-6.
    Ando H; Miyamoto T; Kashima H; Higuchi S; Ida K; Mvunta DH; Shiozawa T
    Horm Cancer; 2017 Aug; 8(4):257-267. PubMed ID: 28516379
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Systematic dissection of the mechanisms underlying progesterone receptor downregulation in endometrial cancer.
    Yang S; Jia Y; Liu X; Winters C; Wang X; Zhang Y; Devor EJ; Hovey AM; Reyes HD; Xiao X; Xu Y; Dai D; Meng X; Thiel KW; Domann FE; Leslie KK
    Oncotarget; 2014 Oct; 5(20):9783-97. PubMed ID: 25229191
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The histone deacetylase inhibitor panobinostat exerts anticancer effects on esophageal squamous cell carcinoma cells by inducing cell cycle arrest.
    Cheng YW; Liao LD; Yang Q; Chen Y; Nie PJ; Zhang XJ; Xie JJ; Shan BE; Zhao LM; Xu LY; Li EM
    Cell Biochem Funct; 2018 Dec; 36(8):398-407. PubMed ID: 30484863
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Epigenetic-mediated upregulation of progesterone receptor B gene in endometrial cancer cell lines.
    Xiong Y; Dowdy SC; Gonzalez Bosquet J; Zhao Y; Eberhardt NL; Podratz KC; Jiang SW
    Gynecol Oncol; 2005 Oct; 99(1):135-41. PubMed ID: 16024066
    [TBL] [Abstract][Full Text] [Related]  

  • 7. HDAC gene expression in pancreatic tumor cell lines following treatment with the HDAC inhibitors panobinostat (LBH589) and trichostatine (TSA).
    Mehdi O; Françoise S; Sofia CL; Urs G; Kevin Z; Bernard S; Igor S; Anabela CD; Dominique L; Eric M; Ali O
    Pancreatology; 2012; 12(2):146-55. PubMed ID: 22487525
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The HDAC inhibitor LBH589 (panobinostat) is an inhibitory modulator of aromatase gene expression.
    Chen S; Ye J; Kijima I; Evans D
    Proc Natl Acad Sci U S A; 2010 Jun; 107(24):11032-7. PubMed ID: 20534486
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Knockdown of MTDH sensitizes endometrial cancer cells to cell death induction by death receptor ligand TRAIL and HDAC inhibitor LBH589 co-treatment.
    Meng X; Brachova P; Yang S; Xiong Z; Zhang Y; Thiel KW; Leslie KK
    PLoS One; 2011; 6(6):e20920. PubMed ID: 21687633
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The HDAC inhibitor LBH589 induces ERK-dependent prometaphase arrest in prostate cancer via HDAC6 inactivation and down-regulation.
    Chuang MJ; Wu ST; Tang SH; Lai XM; Lai HC; Hsu KH; Sun KH; Sun GH; Chang SY; Yu DS; Hsiao PW; Huang SM; Cha TL
    PLoS One; 2013; 8(9):e73401. PubMed ID: 24023871
    [TBL] [Abstract][Full Text] [Related]  

  • 11. DNA microarray profiling of genes differentially regulated by the histone deacetylase inhibitors vorinostat and LBH589 in colon cancer cell lines.
    LaBonte MJ; Wilson PM; Fazzone W; Groshen S; Lenz HJ; Ladner RD
    BMC Med Genomics; 2009 Nov; 2():67. PubMed ID: 19948057
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The prostate cancer blocking potential of the histone deacetylase inhibitor LBH589 is not enhanced by the multi receptor tyrosine kinase inhibitor TKI258.
    Vallo S; Mani J; Stastny M; Makarević J; Juengel E; Tsaur I; Bartsch G; Haferkamp A; Blaheta RA
    Invest New Drugs; 2013 Apr; 31(2):265-72. PubMed ID: 22801803
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The antimelanoma activity of the histone deacetylase inhibitor panobinostat (LBH589) is mediated by direct tumor cytotoxicity and increased tumor immunogenicity.
    Woods DM; Woan K; Cheng F; Wang H; Perez-Villarroel P; Lee C; Lienlaf M; Atadja P; Seto E; Weber J; Sotomayor EM; Villagra A
    Melanoma Res; 2013 Oct; 23(5):341-8. PubMed ID: 23963286
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The HDAC inhibitor, panobinostat, induces apoptosis by suppressing the expresssion of specificity protein 1 in oral squamous cell carcinoma.
    Jeon YJ; Ko SM; Cho JH; Chae JI; Shim JH
    Int J Mol Med; 2013 Oct; 32(4):860-6. PubMed ID: 23877235
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Chromatin composition alterations and the critical role of MeCP2 for epigenetic silencing of progesterone receptor-B gene in endometrial cancers.
    Chu Y; Wang Y; Zhang G; Chen H; Dowdy SC; Xiong Y; Liu F; Zhang R; Li J; Jiang SW
    Cell Mol Life Sci; 2014 Sep; 71(17):3393-408. PubMed ID: 24531693
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The pan-histone deacetylase inhibitor LBH589 (panobinostat) alters the invasive breast cancer cell phenotype.
    Fortunati N; Marano F; Bandino A; Frairia R; Catalano MG; Boccuzzi G
    Int J Oncol; 2014 Mar; 44(3):700-8. PubMed ID: 24366407
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effects of Histone Deacetylase Inhibitor Panobinostat (LBH589) on Bone Marrow Mononuclear Cells of Relapsed or Refractory Multiple Myeloma Patients and Its Mechanisms.
    Ma Y; Liu W; Zhang L; Jia G
    Med Sci Monit; 2017 Oct; 23():5150-5157. PubMed ID: 29080899
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Progesterone receptors induce FOXO1-dependent senescence in ovarian cancer cells.
    Diep CH; Charles NJ; Gilks CB; Kalloger SE; Argenta PA; Lange CA
    Cell Cycle; 2013 May; 12(9):1433-49. PubMed ID: 23574718
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Low dose histone deacetylase inhibitor, LBH589, potentiates anticancer effect of docetaxel in epithelial ovarian cancer via PI3K/Akt pathway in vitro.
    Chao H; Wang L; Hao J; Ni J; Chang L; Graham PH; Kearsley JH; Li Y
    Cancer Lett; 2013 Feb; 329(1):17-26. PubMed ID: 22995071
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Influence of a novel histone deacetylase inhibitor panobinostat (LBH589) on the growth of ovarian cancer.
    Garrett LA; Growdon WB; Rueda BR; Foster R
    J Ovarian Res; 2016 Sep; 9(1):58. PubMed ID: 27633667
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.